Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression.
Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
Birth Outcomes in Newborns Fathered by Men with Multiple Sclerosis Exposed to Disease-Modifying Drugs.
Anti-Human Herpesvirus 6A/B IgG Correlates with Relapses and Progression in Multiple Sclerosis.
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
A study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis (TENERE)
Interleukin-1beta promotes repair of the CNS.
B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients.
Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study.
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study.
T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion.
Neuroprotective effects of resident microglia following acute brain injury.
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.
Therapeutic effects of systemic administration of chaperone αB-crystallin associated with binding proinflammatory plasma proteins.
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
Spotlight on teriflunomide.
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Relationship between disease-modifying therapy and depression in multiple sclerosis.
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Brain reserve against physical disability progression over 5 years in multiple sclerosis.
Biogen Idec's TECFIDERA™ (dimethyl fumarate) approved in US as a first-line oral treatment for multiple sclerosis
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?

Pages